Přihlásit se Zaregistrujte se zdarma

Výnosy R/R společnosti Cue Biopharma Inc

Jaká je hodnota metriky Výnosy R/R společnosti Cue Biopharma Inc?

Hodnota metriky Výnosy R/R společnosti Cue Biopharma Inc je 363.92%

Jaká je definice metriky Výnosy R/R?

Roční růst tržeb za poslední 3 roky (Revenue Y/Y) představuje růst tržeb z roku na rok zprůměrovaný za poslední 3 roky.

The yearly revenue growth rate is calculated as the percentage change in revenue over the trailing twelve months. For this specific metric, the calculation takes into account a series of the last eight quarterly revenues. The revenue growth is useful for determining the success of the company expanding its main business. Revenue growth of 5% to 10% is usually considered good for large-cap companies. For other companies, a sales growth of over 10% is more desirable.

Výnosy R/R společností v sektoru Health Care sektor na NASDAQ ve srovnání se společností Cue Biopharma Inc

Čemu se věnuje společnost Cue Biopharma Inc?

cue biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. we design biologics to engage and modulate the activity of disease-associated t cells in the patient’s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. we believe our biologics allow us to target antigen-specific t cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the cue biologics platform. this flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. headquartered in kendall square, cambridge, ma, we are led by an experienced management team and sci

Firmy s metrikou výnosy r/r podobnou společnosti Cue Biopharma Inc